|View printer-friendly version|
|September 14, 2001 11:38 a.m.|
|Teva Pharmaceutical Industries Announce Interim Results of Coral Study|
Jerusalem, September 14, 2001 - Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) today announced that an interim analysis of its Coral (oral Copaxone) trial showed a trend for a treatment effect in favor of the higher oral dose in patients who were treated for more than a year, although the difference has not reached statistical significance. The independent Data Safety Monitoring Committee (DSMC) that has been monitoring the trial has recommended continuing the trial to its completion by October 2001. As previously reported by Teva, the oral formulation could not be available for commercial use prior to 2003.